Literature DB >> 17093027

Evaluation of commercial rubella immunoglobulin G avidity assays.

Samira Mubareka1, Hannah Richards, Michael Gray, Graham A Tipples.   

Abstract

We compared the performances of five commercial rubella virus immunoglobulin G (IgG) avidity assays. The Adaltis (kappa = 0.28) and Diesse (kappa = 0.33) assays showed poor correlation, the Behring assay (kappa = 0.68) showed good correlation, and the Euroimmun (kappa = 0.95) and Radim (kappa = 0.94) assays showed excellent correlation with a well-established in-house rubella virus IgG avidity assay. The Euroimmun and Radim assays were statistically significantly better than the other commercial assays (P < 0.01).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093027      PMCID: PMC1828953          DOI: 10.1128/JCM.01243-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

Review 1.  Interpretation of rubella serology in pregnancy--pitfalls and problems.

Authors:  Jennifer M Best; Siobhan O'Shea; Graham Tipples; Nicholas Davies; Saleh M Al-Khusaiby; Amanda Krause; Louise M Hesketh; Li Jin; Gisela Enders
Journal:  BMJ       Date:  2002-07-20

2.  Maturation of IgG avidity to individual rubella virus structural proteins.

Authors:  J Nedeljkovic; T Jovanovic; C Oker-Blom
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

3.  Changes in antibody avidity after virus infections: detection by an immunosorbent assay in which a mild protein-denaturing agent is employed.

Authors:  S Inouye; A Hasegawa; S Matsuno; S Katow
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

4.  Differential IgG avidity to rubella virus structural proteins.

Authors:  C A Mauracher; L A Mitchell; A J Tingle
Journal:  J Med Virol       Date:  1992-03       Impact factor: 2.327

5.  Evaluation of rubella IgM enzyme immunoassays.

Authors:  Graham A Tipples; Rasool Hamkar; Talat Mohktari-Azad; Michael Gray; Jennifer Ball; Carol Head; Samuel Ratnam
Journal:  J Clin Virol       Date:  2004-07       Impact factor: 3.168

6.  An ELISA for the estimation of high-avidity and total specific IgG and IgM antibodies to rubella virus.

Authors:  O P Lehtonen; O H Meurman
Journal:  J Virol Methods       Date:  1982-09       Impact factor: 2.014

7.  Rubella-specific IgG1 avidity: a comparison of methods.

Authors:  H I Thomas; P Morgan-Capner
Journal:  J Virol Methods       Date:  1991 Feb-Mar       Impact factor: 2.014

8.  Persistence of specific IgM and low avidity specific IgG1 following primary rubella.

Authors:  H I Thomas; P Morgan-Capner; G Enders; S O'Shea; D Caldicott; J M Best
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014

9.  Rubella-specific IgG subclass avidity ELISA and its role in the differentiation between primary rubella and rubella reinfection.

Authors:  H I Thomas; P Morgan-Capner
Journal:  Epidemiol Infect       Date:  1988-12       Impact factor: 2.451

Review 10.  Rubella.

Authors:  J E Banatvala; D W G Brown
Journal:  Lancet       Date:  2004-04-03       Impact factor: 79.321

View more
  4 in total

Review 1.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

2.  Development of a rapid and convenient method for determination of rubella virus-specific immunoglobulin G avidity.

Authors:  Christelle Vauloup-Fellous; Jessica Ursulet-Diser; Liliane Grangeot-Keros
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

3.  The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up.

Authors:  M J Kemna; W Schlumberger; P van Paassen; C Dähnrich; J G M C Damoiseaux; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2016-05-23       Impact factor: 4.330

Review 4.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.